White Paper

Selecting In Vitro Dissolution Methodologies For Amorphous Solid Dispersions

Source: Lonza

By Deanna Mudie Ph.D., Principal Scientist, Lonza


Achieving good in vivo performance is a key attribute for ensuring safety and efficacy of oral solid dosage (OSD) forms intended for systemic delivery. Yet, new drug targets and mechanisms of action continue to drive drug candidates’ physical properties towards poorly soluble, biopharmaceutics classification system (BCS) II or IV designation.1 Applying bioavailability enhancement techniques can help improve not only the water solubility and oral absorption of OSD drug products but also increase patient safety, efficacy, and compliance. With the availability of so many types of in vitro dissolution tests, though, how do you determine which one will be most effective in predicting in vivo performance of your BCS II or IV drug product?

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma